V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240015430 | 240008838 | 1.59 | 64.35 | Disease modification (D) | 2018-11-17 | 2018-12-03 | Vinblastine | N | null | 240020387 | RITUXIMAB + TEMOZOLOMIDE |
| 240015431 | 240012721 | 1.61 | null | Palliative (P) | null | 2019-09-12 | DACTINOMYCIN + CYCLO + VINCRISTINE | null | N | 240020689 | CVD |
| 240015432 | 240008847 | 1.65 | 55.9 | Palliative (P) | 2016-08-01 | 2016-08-07 | R-GEM-P | 02 | N | 240020798 | CVD |
| 240015433 | 240012726 | 1.58 | 91 | Disease modification (D) | 2016-01-13 | 2016-01-21 | CLADRIBINE | 02 | N | 240020856 | DHAP - R |
| 240015434 | 240008858 | 1.8 | 78 | Disease modification (D) | 2016-11-24 | 2016-11-24 | Carboplatin + Liposomal Doxorubicin | 2 | N | 240021157 | AML17 TRIAL |
| 240015435 | 240014549 | null | 73.6 | Neo-adjuvant (N) | 2016-08-26 | 2016-09-01 | Vinblastine | 02 | N | 240021189 | CYTARABINE + METHOTREXATE |
| 240015436 | 240008863 | null | 78.7 | Palliative (P) | 2016-03-02 | 2016-03-10 | Carboplatin + Liposomal Doxorubicin | 2 | N | 240021253 | OFATUMUMAB |
| 240015437 | 240008868 | 1.77 | null | Palliative (P) | 2017-02-01 | 2017-05-06 | R ABVD | N | N | 240021767 | CTD |
| 240015438 | 240008877 | 0 | 40.2 | Disease modification (D) | 2014-04-10 | 2014-06-27 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | 02 | N | 240022028 | GEMCITABINE + OXALIPLATIN |
| 240015439 | 240008881 | 1.69 | 62.45 | Adjuvant (A) | 2017-01-13 | 2017-09-25 | VAC | N | N | 240022117 | BORTEZOMIB + RITUXIMAB |
| 240015440 | 240008882 | 1.63 | 79.3 | Neo-adjuvant (N) | 2016-02-23 | 2016-05-04 | AML18 PILOT TRIAL | Y | Y | 240022121 | TOPOTECAN |
| 240015441 | 240008884 | 1.61 | 68 | Curative (C) | null | 2018-05-22 | Liposomal Doxorubicin 40mg/m2 | N | null | 240022298 | CISPLATIN + FLUOROURACIL |
| 240015442 | 240008889 | 1.67 | 54 | Disease modification (D) | 2013-04-08 | 2013-05-04 | MABCUTE TRIAL | N | null | 240022512 | BENDAMUSTINE + BORTEZOMIB |
| 240015443 | 240008892 | 1.92 | 83 | Curative (C) | 2018-08-08 | 2018-08-17 | Ofatumumab Loading | 02 | null | 240022526 | IELSG32 TRIAL |
| 240015444 | 240012750 | 0 | 41 | Disease modification (D) | 2014-12-14 | 2014-12-14 | CISPLATIN + FLUOROURACIL | N | N | 240022609 | CVD |
| 240015445 | 240008897 | 1.75 | null | Disease modification (D) | 2017-10-08 | 2018-06-12 | Cyclophos + Dex + Lenalidomide | 01 | N | 240022676 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 240015446 | 240014560 | 1.61 | 75 | Disease modification (D) | 2017-12-09 | 2018-02-16 | PEMBROLIZUMAB | 2 | N | 240022998 | CISPLATIN + FLUOROURACIL |
| 240015447 | 240008905 | 1.6 | 63 | Disease modification (D) | 2015-12-22 | 2015-12-22 | Nelarabine | N | N | 240023081 | MABCUTE TRIAL |
| 240015448 | 240008909 | 1.64 | 70.4 | Disease modification (D) | 2018-02-08 | 2018-03-03 | CISPLATIN + FLUOROURACIL + RT | 02 | N | 240023200 | PILOT TRIAL |
| 240015449 | 240008912 | 1.67 | null | Disease modification (D) | 2014-11-29 | 2014-12-01 | GEM-P | N | null | 240023318 | DOXORUBICIN |
| 240015450 | 240008913 | 1.72 | 55.2 | Curative (C) | 2018-03-08 | 2018-03-09 | GEM-P | 2 | N | 240023657 | CYTARABINE INTRATHECAL |
| 240015451 | 240008916 | null | 80 | Curative (C) | 2016-11-24 | 2018-03-04 | CARMUSTINE + THIOTEPA | 02 | N | 240023735 | BLEOMYCIN + CHLORAMBUCIL + LOMUSTINE + METHOTREXATE + RITUXIMAB + VINBLASTINE |
| 240015452 | 240008920 | 1.68 | null | null | 2014-11-30 | 2015-02-15 | ECX | N | N | 240023752 | VEDEX |
| 240015453 | 240008923 | 1.76 | 74.8 | Adjuvant (A) | 2015-11-25 | 2015-11-29 | IDELALISIB | N | N | 240023933 | UKALL2014 |
| 240015454 | 240008926 | 1.62 | 84 | Curative (C) | 2018-04-11 | 2018-04-19 | REMODLB TRIAL | N | N | 240024118 | CISPLATIN + GEMCITABINE |
| 240015455 | 240014569 | 1.63 | 68.7 | Curative (C) | 2016-05-06 | 2016-08-19 | CISPLATIN + FLUOROURACIL | N | N | 240024570 | NAB-PACLITAXEL |
| 240015456 | 240008929 | null | 70.4 | Palliative (P) | 2016-06-28 | 2016-07-02 | Triple / Double Intrathecal Therapy | N | N | 240024747 | CYTARABINE HIGH DOSE |
| 240015457 | 240008931 | 1.84 | 61.5 | Curative (C) | 2018-10-18 | 2018-11-01 | MYELOMA XI TRIAL | N | N | 240025194 | TRIPLE INTRATHECAL |
| 240015458 | 240014572 | 1.69 | 77 | Palliative (P) | 2018-03-15 | 2018-03-20 | Irinotecan + Modified De Gramont | N | N | 240025582 | REMODL TRIAL |
| 240015459 | 240012777 | 1.64 | 92.6 | Curative (C) | 2017-08-04 | 2017-08-13 | Cytarabine HD + Methotrexate HD | N | N | 240025641 | GEMCITABINE + PACLITAXEL |
| 240015460 | 240008938 | 1.63 | 54.2 | Palliative (P) | 2013-10-21 | 2013-10-21 | CTD | N | N | 240026056 | NILOTINIB |
| 240015461 | 240015936 | 1.65 | 81.8 | Disease modification (D) | 2015-12-03 | 2016-01-11 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | N | N | 240027348 | DOCETAXEL |
| 240015462 | 240008948 | 1.66 | 73 | Palliative (P) | 2018-04-24 | 2018-04-30 | VEDex | N | N | 240028005 | ICE-R |
| 240015463 | 240012784 | 1.74 | null | Curative (C) | 2018-09-20 | 2018-11-05 | AML17 TRIAL | N | N | 240028943 | PILOT TRIAL |
| 240015464 | 240014578 | 1.63 | 115 | Palliative (P) | 2017-03-07 | 2017-03-11 | DACARBAZINE + DOXORUBICIN + VINBLASTINE | 02 | N | 240028966 | BENDAMUSTINE + BORTEZOMIB |
| 240015465 | 240008963 | 1.54 | 119 | Curative (C) | 2016-08-11 | 2016-08-15 | PEMBROLIZUMAB | 02 | N | 240030162 | DOCETAXEL |
| 240015466 | 240008970 | 1.85 | 79.4 | Palliative (P) | 2016-09-19 | 2018-09-15 | Vinorelbine (oral) | N | N | 240030629 | CISPLATIN + GEMCITABINE |
| 240015467 | 240012793 | null | null | Curative (C) | 2016-01-09 | 2016-01-09 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 2 | N | 240030743 | IRINOTECAN + MDG |
| 240015468 | 240008976 | 1.62 | 91.4 | Unknown (U) | 2018-03-06 | 2018-03-06 | Mitoxantrone | N | Y | 240031120 | ICE-R |
| 240015469 | 240008978 | 1.71 | 0 | Palliative (P) | 2016-05-15 | 2016-06-27 | AML 18 Pilot Trial | N | N | 240031751 | BENDAMUSTINE + OFATUMUMAB |
| 240015470 | 240014583 | 1.65 | 44.7 | Curative (C) | 2016-09-19 | 2017-05-20 | AML 19 TRIAL | 02 | N | 240032004 | CISPLATIN + GEMCITABINE |
| 240015471 | 240008983 | 1.73 | 54.6 | Curative (C) | 2017-01-23 | 2017-01-23 | Cytarabine intrathecal | Y | N | 240032220 | BLEOMYCIN + CHLORAMBUCIL + LOMUSTINE + METHOTREXATE + RITUXIMAB + VINBLASTINE |
| 240015472 | 240008985 | 1.55 | 70 | Curative (C) | 2018-07-13 | 2018-07-13 | Cetuximab 7 day (>Cycle 2) | N | N | 240032654 | CISPLATIN + GEMCITABINE |
| 240015473 | 240012800 | null | 91 | Palliative (P) | 2016-01-16 | 2016-01-16 | BORTEZOMIB + THALIDOMIDE | 2 | N | 240032911 | CTD |
| 240015474 | 240008986 | 1.88 | 87.7 | Palliative (P) | 2013-12-09 | 2013-12-29 | CODOX M | N | N | 240033328 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240015475 | 240008992 | 1.8 | 75.2 | Curative (C) | 2015-04-28 | 2016-01-07 | DHAP - R | 02 | N | 240034000 | AML19 TRIAL |
| 240015476 | 240008994 | 1.53 | 98.6 | Palliative (P) | 2015-12-04 | 2015-12-07 | PEMBROLIZUMAB | 02 | N | 240034037 | CYTARABINE INTRATHECAL |
| 240015477 | 240008997 | 1.7 | 70 | Curative (C) | 2016-07-27 | 2016-07-27 | AML 19 TRIAL | 02 | N | 240034474 | IXAZOMIB + LENALIDOMIDE |
| 240015478 | 240008998 | 1.6 | 74 | Curative (C) | 2019-05-29 | 2019-06-06 | ESHAP | 02 | N | 240035260 | UKALL2014 |
| 240015479 | 240009000 | null | 79 | null | 2018-02-01 | 2018-02-14 | DA-EPOCH-R | 02 | null | 240035615 | DABRAFENIB + TRAMETINIB |